BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
BioCryst Pharmaceuticals announced that Japan's Ministry of Health, Labor and Welfare has approved ORLADEYO (berotralstat) for prophylactic treatment of hereditary angioedema (HAE) in pediatric patients aged 2 to under 12 years. This is the first and only oral prophylactic therapy approved for this age group in Japan. The approval is based on posit…